Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 16,814 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Symptom Clusters Clear all
Withdrawn Not applicable Interventional

Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock

NCT01063010
View directory record Official record
Conditions
Septic Shock
Interventions
Bevacizumab, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Camden, New Jersey • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Group Prenatal Care for Reducing the Risk of STDs in Pregnant Young Women

NCT00271960
View directory record Official record
Conditions
Sexually Transmitted Diseases, HIV Infections
Interventions
CenteringPregnancy, CenteringPregnancyPlus, Usual care
Behavioral
Lead sponsor
Yale University
Other
Eligibility
14 Years to 25 Years · Female only
Enrollment
1,047 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
2
States / cities
New Haven, Connecticut • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 1 Interventional Results available

Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK

NCT05873062
View directory record Official record
Conditions
Myoclonus Epilepsies, Progressive
Interventions
AUT00201, Placebo
Drug
Lead sponsor
Autifony Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury

NCT00036062
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Acute Lung Injury
Interventions
Sivelestat
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

NCT04542070
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 1 Interventional

Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors

NCT00003597
View directory record Official record
Conditions
Cancer
Interventions
recombinant human thrombopoietin, carboplatin, etoposide, ifosfamide, G-CSF
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

NCT00451997
View directory record Official record
Conditions
Leukemia, Myeloid, Myelodysplastic Syndromes
Interventions
Gleevec, Ara-C
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Not applicable Interventional

Mild Intermittent Hypoxia and Its Multipronged Effect on Sleep Apnea

NCT03736382
View directory record Official record
Conditions
Obstructive Sleep Apnea, Spinal Cord Injuries
Interventions
Mild intermittent hypoxia, Sham protocol, Continuous positive airway pressure (CPAP)
Other
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)

NCT02040623
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo Ophthalmic Solution
Drug · Other
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Plantation, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

NCT00002423
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Lamivudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 1 Interventional

Safety Study of TPI-287 to Treat CBS and PSP

NCT02133846
View directory record Official record
Conditions
Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Interventions
TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo, TPI-287 6.3 mg/m2
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nicotine Treatment of Cognitive Decline in Down Syndrome

NCT01778946
View directory record Official record
Conditions
Down Syndrome, Mild Cognitive Impairment
Interventions
Low Dose Nicotine (7mg), Moderate Dose Nicotine (14mg)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
25 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects

NCT01593046
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744 Oral, GSK1265744 LAP 800mg intramuscular injection, GSK1265744 LAP 200mg subcutaneous injection, GSK1265744 LAP 200mg intramuscular injection, GSK1265744 LAP 400mg intramuscular injection, TMC278 LA 1200mg intramuscular injection, TMC278 LA 600mg intramuscular injection
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 64 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Daytona Beach, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 1 Interventional

Study of the Effect of GS-6615 in Subjects With LQT-3

NCT01849003
View directory record Official record
Conditions
Long QT Syndrome
Interventions
GS-6615
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Oct 25, 2026, 5:59 AM EDT
Completed No phase listed Observational

Cytokine Gene Polymorphisms in Bone Marrow Failure

NCT00085670
View directory record Official record
Conditions
Bone Marrow Diseases
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

NCT02226120
View directory record Official record
Conditions
Chronic Heart Failure With Reduced Ejection Fraction
Interventions
LCZ696
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
1,980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
24
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Little Rock, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 25, 2026, 5:59 AM EDT
Terminated Phase 1 Interventional

Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)

NCT03118479
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Kallmann Syndrome
Interventions
Anastrozole Pill, Testosterone, Placebo Oral Tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Not applicable Interventional Results available

Post-bypass Prophylactic IVIG in Infants and Neonates

NCT02043379
View directory record Official record
Conditions
Hypogammaglobulinemia, Congenital Heart Disease
Interventions
IVIG, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 6 Months
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 25, 2026, 5:59 AM EDT
Completed No phase listed Observational

Hormonal Regulation of Puberty and Fertility

NCT01511588
View directory record Official record
Conditions
Endocrine Disease, Infertility, Hypogonadism, Amenorrhea, Adolescents
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
14 Years to 100 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
2
States / cities
Bethesda, Maryland • Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 25, 2026, 5:59 AM EDT
Completed No phase listed Observational

Reproductive Health in Men and Women With Vasculitis

NCT02176070
View directory record Official record
Conditions
Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

NCT00119873
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
3
States / cities
San Francisco, California • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Love Infection: A Dramatized Story Intervention (Telenovela/Soap Opera) for HIV Prevention

NCT05358366
View directory record Official record
Conditions
HIV Infections
Interventions
Infeccion de Amor (Love Infection)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 25, 2026, 5:59 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Ileocecal Sphincter Reflex by Cecal Distension During Colonoscopy

NCT01413945
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
20 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Early Phase 1 Interventional

Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant

NCT01959477
View directory record Official record
Conditions
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Childhood Anaplastic Large Cell Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage I Childhood Large Cell Lymphoma, Stage I Childhood Lymphoblastic Lymphoma, Stage I Childhood Small Noncleaved Cell Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Childhood Anaplastic Large Cell Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage II Childhood Large Cell Lymphoma, Stage II Childhood Lymphoblastic Lymphoma, Stage II Childhood Small Noncleaved Cell Lymphoma, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Childhood Anaplastic Large Cell Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage III Childhood Lymphoblastic Lymphoma, Stage III Childhood Small Noncleaved Cell Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Childhood Anaplastic Large Cell Lymphoma, Stage IV Childhood Hodgkin Lymphoma, Stage IV Childhood Large Cell Lymphoma, Stage IV Childhood Lymphoblastic Lymphoma, Stage IV Childhood Small Noncleaved Cell Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
busulfan, etoposide, cyclophosphamide, peripheral blood stem cell transplantation, autologous hematopoietic stem cell transplantation
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
2 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 25, 2026, 5:59 AM EDT